2型糖尿病早期有效血糖和体重管理的研究综述

IF 6.1 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2025-03-06 Epub Date: 2025-01-28 DOI:10.1111/dom.16206
Alice Y. Y. Cheng MD, Robert J. Heine MD, Stefano Del Prato MD, Jennifer B. Green MD, Vivian Thuyanh Thieu PhD, Meltem Zeytinoglu MD
{"title":"2型糖尿病早期有效血糖和体重管理的研究综述","authors":"Alice Y. Y. Cheng MD,&nbsp;Robert J. Heine MD,&nbsp;Stefano Del Prato MD,&nbsp;Jennifer B. Green MD,&nbsp;Vivian Thuyanh Thieu PhD,&nbsp;Meltem Zeytinoglu MD","doi":"10.1111/dom.16206","DOIUrl":null,"url":null,"abstract":"<p>Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a ‘legacy effect’, where early treatment to reach glycaemic targets is associated with enduring long-term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β-cell function decline, they have been unable to address one of the underlying causal abnormalities—excess adiposity. Here, we review currently available evidence for the beneficial long-term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 4","pages":"1708-1718"},"PeriodicalIF":6.1000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16206","citationCount":"0","resultStr":"{\"title\":\"Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review\",\"authors\":\"Alice Y. Y. Cheng MD,&nbsp;Robert J. Heine MD,&nbsp;Stefano Del Prato MD,&nbsp;Jennifer B. Green MD,&nbsp;Vivian Thuyanh Thieu PhD,&nbsp;Meltem Zeytinoglu MD\",\"doi\":\"10.1111/dom.16206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a ‘legacy effect’, where early treatment to reach glycaemic targets is associated with enduring long-term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β-cell function decline, they have been unable to address one of the underlying causal abnormalities—excess adiposity. Here, we review currently available evidence for the beneficial long-term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"27 4\",\"pages\":\"1708-1718\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16206\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dom.16206\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.16206","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

尽管关键指南承认实现早期血糖控制对2型糖尿病(T2D)患者有重要益处,并且解决过度肥胖是全面的以人为本的T2D护理的核心组成部分之一,但仍有相当一部分T2D患者未达到其代谢治疗目标。先前的治疗模式受到重要的治疗相关风险的限制,如低血糖和体重增加。因此,通常采用更保守、顺序的治疗方法。这种方法的一个潜在后果是错过了实现“遗留效应”的机会,即早期治疗达到血糖目标与T2D的持久长期益处相关。此外,虽然以前的治疗方法已经解决了t2dm的核心缺陷,包括胰岛素抵抗和β细胞功能下降,但它们无法解决其中一个潜在的病因异常-过度肥胖。在这里,我们回顾了目前可用的证据,证明早期血糖控制和体重管理对t2dm患者有益的长期影响,并讨论了潜在的下一步措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review

Despite the recognition by key guidelines that achieving early glycaemic control has important benefits in individuals with type 2 diabetes (T2D) and that addressing excess adiposity is one of the central components of comprehensive person-centred T2D care, a substantial proportion of individuals with T2D do not meet their metabolic treatment goals. Prior treatment paradigms were limited by important treatment-associated risks such as hypoglycaemia and body weight gain. Therefore, a more conservative, sequential approach to treatment was typically utilized. One potential consequence of this approach has been a missed opportunity to achieve a ‘legacy effect’, where early treatment to reach glycaemic targets is associated with enduring long-term benefits in T2D. Additionally, while previous treatment approaches have addressed core defects in T2D, including insulin resistance and β-cell function decline, they have been unable to address one of the underlying causal abnormalities—excess adiposity. Here, we review currently available evidence for the beneficial long-term effects of early glycaemic control and management of body weight in people with T2D and discuss potential next steps.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Screening for type 1 diabetes in patients with celiac or thyroid disease: Practical considerations. Increased risk of type 1 diabetes in patients with autoimmune conditions-Further nuance needed. Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization (STOP DIABETES). Dietary Fibre, Gut Microbiota and Cardiovascular Outcomes: Differential Associations by Diabetes Status in Multiethnic Cohorts. Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1